Cargando…

Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration

Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic neoplasms characterized by ineffective hematopoiesis and myelodysplasia with a variable spectrum of clinical–biological features that can be used to build a prognostic estimation. This review summarizes the current most widely used...

Descripción completa

Detalles Bibliográficos
Autor principal:	Chen-Liang, Tzu-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151135/ https://www.ncbi.nlm.nih.gov/pubmed/34064707 http://dx.doi.org/10.3390/jcm10102052

Ejemplares similares

Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy
por: Bond, Danielle R., et al.
Publicado: (2020)

Current challenges and unmet medical needs in myelodysplastic syndromes
por: Platzbecker, Uwe, et al.
Publicado: (2021)

The Genetics of Myelodysplastic Syndromes: Clinical Relevance
por: Chiereghin, Chiara, et al.
Publicado: (2021)

Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists
por: Crisà, Elena, et al.
Publicado: (2021)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Identification of a metabolic gene panel to predict the prognosis of myelodysplastic syndrome
por: Hu, Fang, et al.
Publicado: (2020)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Genetics of Myelodysplastic Syndromes
por: Saygin, Caner, et al.
Publicado: (2021)

Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
por: Clara, Joseph A., et al.
Publicado: (2016)

Myelodysplastic syndromes and overlap syndromes
por: Chang, Yoon Hwan
Publicado: (2021)

Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic
por: Flores-Figueroa, Eugenia, et al.
Publicado: (2016)

Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
por: Cassanello, Giulio, et al.
Publicado: (2022)

Telomere integrated scoring system of myelodysplastic syndrome
por: Park, Hee Sue, et al.
Publicado: (2023)

The genomic landscape of pediatric myelodysplastic syndromes
por: Schwartz, Jason R., et al.
Publicado: (2017)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Immune Mechanisms in Myelodysplastic Syndrome
por: Glenthøj, Andreas, et al.
Publicado: (2016)

Hereditary Predispositions to Myelodysplastic Syndrome
por: Bannon, Sarah A., et al.
Publicado: (2016)

Prognostic Markers of Myelodysplastic Syndromes
por: Veryaskina, Yuliya Andreevna, et al.
Publicado: (2020)

Genetic basis of myelodysplastic syndromes
por: OGAWA, Seishi
Publicado: (2020)

Myelodysplastic Syndrome: Diagnosis and Screening
por: Tria, Francisco P., et al.
Publicado: (2022)

The Mesenchymal Niche in Myelodysplastic Syndromes
por: Friedrich, Chloé, et al.
Publicado: (2022)

Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
por: Guo, Xinyu, et al.
Publicado: (2023)

Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome
por: Chen, Ying, et al.
Publicado: (2023)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Is dynamic thiol/disulfide homeostasis associated with the prognosis of myelodysplastic syndrome?
por: Ali, Ucar Mehmet, et al.
Publicado: (2020)

Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis
por: Moiseev, Ivan, et al.
Publicado: (2022)

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
por: McCormack, Steven E, et al.
Publicado: (2010)

Myelodysplastic syndrome from theoretical review to clinical application view
por: Mohammad, Amrallah A.
Publicado: (2018)

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications
por: Simoni, Yannick, et al.
Publicado: (2022)

Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
por: Rodriguez-Sevilla, Juan Jose, et al.
Publicado: (2023)

Development and validation of a novel prognosis prediction model for patients with myelodysplastic syndrome
por: Liang, Haiping, et al.
Publicado: (2022)

Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Myelodysplastic syndrome with genetic predisposition
por: Park, Meerim
Publicado: (2021)

Cytogenetic features in myelodysplastic syndromes
por: Haase, Detlef
Publicado: (2008)

New Treatments for Myelodysplastic Syndromes
por: D’Alò, Francesco, et al.
Publicado: (2010)

Molecular Pathogenesis of Myelodysplastic Syndromes
por: Visconte, Valeria, et al.
Publicado: (2014)

Diagnostics and Prognostication of Myelodysplastic Syndromes
por: Zini, Gina
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hd9dr4s234msi4pbe34sos3k64